The Current States, Challenges, Ongoing Efforts, and Future Perspectives of Pharmaceutical Excipients in Pediatric Patients in Each Country and Region

• Egile Nagusiak: Jumpei Saito (Egilea), Anjali Agrawal (Egilea), Vandana Patravale (Egilea), Anjali Pandya (Egilea), Samuel Orubu (Egilea), Min Zhao (Egilea), Gavin P. Andrews (Egilea), Caroline Petit-Turcotte (Egilea), Hannah Landry (Egilea), Alysha Croker (Egilea), Hidefumi Nakamura (Egilea), Akimasa Yamatani (Egilea), Smita Salunke (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2022-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

A major hurdle in pediatric formulation development is the lack of safety and toxicity data on some of the commonly used excipients. While the maximum oral safe dose for several kinds of excipients is known in the adult population, the doses in pediatric patients, including preterm neonates, are not...